Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

NCT06332755 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer(NSCLC)
Head and Neck Squamous Cell Carcinoma(HNSCC)
Renal Cell Carcinoma(RCC)
Urothelial Carcinoma
Malignant Melanoma

Interventions

DRUG: Phase 1a: LB-LR1109
DRUG: Phase 1b: LB-LR1109 and Atezolizumab

Sponsor

LG Chem